Citations

Mayo Clinic

Clear

1818 citation(s) found for "Israel, E".

Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation
McMurray, John J.V. , Ezekowitz, Justin A. , Amerena, John , Commerford, Patrick, Oh, Byung‐Hee , Harjola, Veli‐Pekka , Hanna, Michael G. , Alexander, John H. , Wojdyla, Daniel , Wallentin, Lars , Granger, Christopher B., Granger, Christopher B. , Lewis, Basil S. , Gersh, Bernard J. , Diepen, Sean van , Bartúnek, Jozef , Al‐Khatib, Sana M. , Lópes, Renato D. , McMurray, John J V , Granger, Christopher B

Circulation: Heart Failure | April 11, 2013 | Volume: 6 | Issue: 3 | Pages: 451-460

10.1161/circheartfailure.112.000143 | PMID 23575255 Get It

Background— We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin. Methods and Results— The risk of a number of outcomes, including the composite of SSE or death (to take account of competing risks) and composite of SSE, major bleeding, or death (net clinical benefit) were calculated in 3 patient groups: (1) no HF/no LVSD (n=8728), (2) HF/no LVSD (n=3207), and (3) LVSD with/without symptomatic HF (n=2736). The rate of both outcomes was highest in patients with LVSD (SSE or death 8.06; SSE, major bleeding, or death 10.46 per 100 patient-years), intermediate for HF but preserved LV systolic function (5.32; 7.24), and lowest in patients without HF or LVSD (1.54; 5.27); each comparison P <0.0001. Each outcome was less frequent in patients treated with apixaban: in all ARISTOTLE patients, the apixaban/warfarin hazard ratio for SSE or death was 0.89 (95% confidence interval, 0.81–0.98; P =0.02); for SSE, major bleed, or death it was 0.85 (0.78–0.92; P <0.001). There was no heterogeneity of treatment effect across the 3 groups. Conclusions— Patients with LVSD (with/without HF) had a higher risk of SSE or death (but similar rate of SSE) compared with patients with HF but preserved LV systolic function; both had a greater risk than patients without either HF or LVSD. Apixaban reduced the risk of both outcomes more than warfarin in all 3 patient groups. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00412984.
Contemporary Ventilator Management in Patients With and at Risk of ALI/ARDS
Chang, Steven Y., Dabbagh, Ousama, Gajic, O, Patrawalla, Amee , Elie, Marie‐Carmelle , Talmor, Daniel , Malhotra, Atul , Adesanya, Adebola, Anderson, Harry L, Blum, James M. , Park, Pauline K. , Gong, Michelle N. , (USCIITG-LIPS), on behalf of the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, (USCIITG-LIPS), the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, Talmor, Daniel S, Bender, S Patrick, Garcia, Mauricio, Hou, Peter C, Barry, Jonathan M, Shempp, Iam, Malhotra, Atul, Frendl, Gyorgy, Ahmed, Adil, Gajic, Ognjen, Malinchoc, Michael, Kor, Daryl J, Afessa, Bekele, Cartin-Ceba, Rodrigo, Gong, Michelle Ng, Gentile, Nina T, Stevenson, Karen, Freeman, Brent, Srinivasan, Sujatha, Sevransky, Jonathan, Chang, Steven Y, Patrawalla, Amee, Elie, Carmelle, Hamdani, Irram, Seiden, Jason, Douglas, Ivor, Mikkelsen, Mark, Christie, Jason D, Gaieski, David F, Lanken, Paul, Meyer, Nuala, Sha, Chirag, Park, Pauline K, Harris, Julie, Napolitano, Lena, Raghavendran, Krishnan, Hyzy, Robert C, Blum, James, Watkins, Timothy R, Deem, Steven, Treggiari, Miriam, Adesanya, Adebola, Sadikot, Ruxana, Hoth, J Jason, Yoza, Barbara, Festic, Emir, Kaufman, David, Bajwa, Ednan, Malhotra, Atul, Thompson, B Taylor, Christiani, David C, Cengiz, Melike, Yilmaz, Murat, Anderson, Harry, Tchorz, Kathryn, McCarthy, Mary C, Uddin, David, Iscimen, Remzi, Dabbagh, Ousama, Kallenbach, Nena, Esper, Anette, Martin, Greg, Bajwa, Ednan K. , Douglas, Ivor S. , Frendl, György , Chang, Steven Y. , Anderson, Harry L, (USCIITG-LIPS), on behalf of the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, (USCIITG-LIPS), the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, Talmor, Daniel S, Bender, S Patrick, Garcia, Mauricio, Hou, Peter C, Barry, Jonathan M, Shempp, Iam, Malhotra, Atul, Frendl, Gyorgy, Ahmed, Adil, Gajic, Ognjen, Malinchoc, Michael, Kor, Daryl J, Afessa, Bekele, Cartin-Ceba, Rodrigo, Gong, Michelle Ng, Gentile, Nina T, Stevenson, Karen, Freeman, Brent, Srinivasan, Sujatha, Sevransky, Jonathan, Chang, Steven Y, Patrawalla, Amee, Elie, Carmelle, Hamdani, Irram, Seiden, Jason, Douglas, Ivor, Mikkelsen, Mark, Christie, Jason D, Gaieski, David F, Lanken, Paul, Meyer, Nuala, Sha, Chirag, Park, Pauline K, Harris, Julie, Napolitano, Lena, Raghavendran, Krishnan, Hyzy, Robert C, Blum, James, Watkins, Timothy R, Deem, Steven, Treggiari, Miriam, Adesanya, Adebola, Sadikot, Ruxana, Hoth, J Jason, Yoza, Barbara, Festic, Emir, Kaufman, David, Bajwa, Ednan, Malhotra, Atul, Thompson, B Taylor, Christiani, David C, Cengiz, Melike, Yilmaz, Murat, Anderson, Harry, Tchorz, Kathryn, McCarthy, Mary C, Uddin, David, Iscimen, Remzi, Dabbagh, Ousama, Kallenbach, Nena, Esper, Anette, Martin, Greg

Respiratory Care | April 6, 2013 | Volume: 58 | Issue: 4 | Pages: 578-588

10.4187/respcare.01755 | PMID 22906363 Get It

Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Yonas E. , Schneider, Lon S. , Gitlin, Laura N. , Smith, Gwenn S. , Evans, Jovier D., Lee, Michael K. , Porsteinsson, Anton P. , Lanctôt, Krista L. , Rosenberg, Paul B. , Sultzer, David L. , Francis, Paul T. , Brodaty, Henry , Padala, Prasad P., Onyike, Chiadikaobi, Ortiz, Luis Agüera, Vitiello, Michael V. , Yaffe, Kristine , Zee, Phyllis C. , Herrmann, Nathan , Ballard, Clive , Khin, Ni A. , Alfaro, Cara L., Murray, Patrick S. , Schultz, Susan K. , Lyketsos, Constantine G. , ISTAART, Neuropsychiatric Syndromes Professional Interest Area of, Miller, David S. , Bell, J. Simon , Padala, Prasad R. , Ancoli‐Israel, Sonia , Bliwise, Donald L. , Martin, Jennifer L. , Sweet, Robert A. , ISTAART, Neuropsychiatric Syndromes Professional Interest Area of, Lanctôt, Krista L , Brodaty, Henry , Ballard, Clive , Geda, Yonas E

Alzheimer's & Dementia | April 4, 2013 | Volume: 9 | Issue: 5 | Pages: 602-608

10.1016/j.jalz.2012.12.001 | PMID 23562430 Get It

Abstract Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS‐PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome‐specific synthetic reviews and recommendations prepared by NPS‐PIA workgroups on depression, apathy, sleep, agitation, and psychosis.
Pain and pain management in polycystic kidney disease
Czarnecki, Peter G. , Steinman, Theodore I.

Polycystic Kidney Disease: from Bench to Bedside | March 26, 2013 | Volume: No volume available | Issue: No issue available | Pages: 114-128

10.2217/ebo.12.137 Get It

Right Ventricular Systolic Function in Organic Mitral Regurgitation
Deswarte, Guillaume, Lamblin, Nicolas , Foucher-Hossein, Claude, Fayad, Georges , Richardson, Marjorie, Polge, Anne‐Sophie, Vannesson, Claire, Topilsky, Yan , Juthier, Françis , Trochu, Jean‐Noël , Enriquez‐Sarano, Maurice , Bauters, Christophe , Tourneau, Thierry Le , Enriquez-Sarano, Maurice , Topilsky, Yan

Circulation | March 14, 2013 | Volume: 127 | Issue: 15 | Pages: 1597-1608

10.1161/circulationaha.112.000999 | PMID 23487435 Get It

Background— To assess the prevalence, determinants, and prognosis value of right ventricular (RV) ejection fraction (EF) impairment in organic mitral regurgitation. Methods and Results— Two hundred eight patients (62±12 years, 138 males) with chronic organic mitral regurgitation referred to surgery underwent an echocardiography and biventricular radionuclide angiography with regional function assessment. Mean RV EF was 40.4±10.2%, ranging from 10% to 65%. RV EF was severely impaired (≤35%) in 63 patients (30%), and biventricular impairment (left ventricular EF<60% and RV EF≤35%) was found in 34 patients (16%). Pathophysiologic correlates of RV EF were left ventricular septal function (β=0.42, P <0.0001), left ventricular end-diastolic diameter index (β=−0.22, P =0.002), and pulmonary artery systolic pressure (β=−0.14, P =0.047). Mitral effective regurgitant orifice size (n=84) influenced RV EF (β=−0.28, P =0.012). In 68 patients examined after surgery, RV EF increased strongly (27.5±4.3–37.9±7.3, P <0.0001) in patients with depressed RV EF, whereas it did not change in others ( P =0.91). RV EF ≤35% impaired 10-year cardiovascular survival (71.6±8.4% versus 89.8±3.7%, P =0.037). Biventricular impairment dramatically reduced 10-year cardiovascular survival (51.9±15.3% versus 90.3±3.2%, P <0.0001; hazard ratio, 5.2; P <0.0001) even after adjustment for known predictors (hazard ratio, 4.6; P =0.004). Biventricular impairment reduced also 10-year overall survival (34.8±13.0% versus 72.6±4.5%, P =0.003; hazard ratio, 2.5; P =0.005) even after adjustment for known predictors ( P =0.048). Conclusions— In patients with organic mitral regurgitation referred to surgery, RV function impairment is frequent (30%) and depends weakly on pulmonary artery systolic pressure but mainly on left ventricular remodeling and septal function. RV function is a predictor of postoperative cardiovascular survival, whereas biventricular impairment is a powerful predictor of both cardiovascular and overall survival.
Evaluation of Treatment Benefit in Journal of Clinical Oncology
Goodwin, Pamela J. , Cannistra, Stephen A., Ballman, Karla V. , Small, Eric J.

Journal of Clinical Oncology | January 29, 2013 | Volume: 31 | Issue: 9 | Pages: 1123-1124

10.1200/jco.2012.47.6952 | PMID 23358984 Get It

Commentary: larazotide acetate ‐ an exciting new development for coeliac patients? Authors’ reply
Kelly, Ciarán P. , Green, P. H. R., DiMarino, Anthony J., Colatrella, Anthony M., Leffler, Daniel A. , Alexander, T. , Arsenescu, Razvan, Jiang, John , Arterburn, L. A., Paterson, Blake, Fedorak, Richard N. , Group, for the Larazotide Acetate Celiac Disease Study, Murray, Joseph A. , León, Francisco , Group, for the Larazotide Acetate Celiac Disease Study, Fedorak, R N

Alimentary Pharmacology & Therapeutics | January 22, 2013 | Volume: 37 | Issue: 4 | Pages: 496-497

10.1111/apt.12196 | PMID 23336684 Get It

Risk Factors for Radiocontrast Nephropathy After Emergency Department Contrast‐enhanced Computerized Tomography
Traub, Stephen J., Kellum, John A. , Tang, Aimee, Cataldo, Lauren, Kancharla, Adarsh, Shapiro, Nathan I. , Kellum, John A

Academic Emergency Medicine | January 14, 2013 | Volume: 20 | Issue: 1 | Pages: 40-45

10.1111/acem.12059 | PMID 23570477 Get It

AbstractObjectivesRadiocontrast nephropathy (RCN) is a known complication of procedures in which intravascular iodinated contrast material is used. The authors sought to determine the risk factors for RCN after emergency department (ED) contrast‐enhanced computerized tomography (CECT).MethodsThis was a retrospective case–control study of patients presenting to a tertiary care ED between January 1, 2004, and December 31, 2006. Inclusion criteria were CECT performed in the ED, serum creatinine measured prior to CECT, and serum creatinine measured 48 to 96 hours after CECT. Exclusion criterion was dialysis‐dependent renal failure prior to CECT. The outcome of RCN was defined as an absolute creatinine increase of greater than or equal to 0.5 mg/dL, or a 25% increase above baseline. The charts of all RCN patients and a random sample of non‐RCN patients were reviewed to document the presence or absence of potential risk factors. Univariate analysis was performed using chi‐square and multiple logistic regression applying a weighted technique to account for sampling of non‐RCN patients.ResultsAmong the 5,006 patients meeting inclusion criteria, 349 (7%) developed RCN. Multiple regression analysis demonstrated that serum creatinine > 2 mg/dL, liver disease, heart failure, hematocrit < 30%, hypertension, and diabetes were risk factors for RCN, whereas age > 75 years, vascular disease, and serum creatinine > 1.5 mg/dL were not. The area under the curve (AUC) for the model was 0.65. Although the risk of RCN increased with the number of risk factors present, we could not develop a model with sufficient diagnostic accuracy to guide clinical decision‐making.ConclusionsThe authors report risk factors for RCN in a large case–control study, but could not develop an accurate decision tool to identify patients at increased risk for RCN after ED CECT.
Designing patient flow in emergency departments
Marmor, Yariv N. , Golany, Boaz, Israelit, Shlomo, Mandelbaum, Avishai

IIE Transactions on Healthcare Systems Engineering | December 20, 2012 | Volume: 2 | Issue: 4 | Pages: 233-247

10.1080/19488300.2012.736118 Get It

Anesthesiology and the Acute Respiratory Distress Syndrome
Kor, Daryl J. , Talmor, Daniel

Anesthesiology | December 4, 2012 | Volume: 118 | Issue: 1 | Pages: 1-4

10.1097/aln.0b013e3182794853 | PMID 23208520 Get It